Biosimilar Insights

  1. Process Intensification Through Downstream Connectivity 7/1/2026

    See how downstream steps can be linked into a coordinated workflow, with practical insight into automation, equipment integration, and process control for building a more efficient strategy.

  2. LNP-Mediated Cell Transfection In Bioreactors Across Workflows 6/24/2026

    Lipid nanoparticles are redefining immune cell engineering. Delve into new data that demonstrates the performance across multiple cell types and bioreactor systems, supporting their potential workflows.

  3. Towards A Universal LNP Platform For Multiplex Engineering 6/19/2026

    Multiplex engineering of T cells for solid tumors requires precise delivery. Emerging LNP approaches enable co-delivery of RNA and DNA, offering a safer, more scalable path beyond viral vectors.

  4. Extrahepatic Delivery Of mRNA-LNP To Spleen 6/19/2026

    In vivo CAR-T approaches aim to reprogram T cells directly in the body using targeted lipid nanoparticles. Improved delivery to immune organs highlights new potential for scalable cell therapies.

  5. mRNA LNPs Drive Safe, Effective Repeat Dosing In Disease Models 6/19/2026

    Repeat dosing may be essential for long-term mRNA applications. Explore safety, immune-response, and efficacy findings from multiple LNP administrations, including a nine-dose evaluation over six months.

  6. Discover A System That Can Be Used With Various Cell Culture Media 6/19/2026

    Evolving CAR T cell therapies are raising the bar for manufacturing. Advances in cell expansion and the shift to serum-free media are redefining how scalable, future-ready processes are designed.

  7. Developing CAR T Therapies With A Cell Therapy Manufacturing Platform 6/19/2026

    Advances in CAR T cell engineering are expanding clinical potential, but manufacturing complexity limits scale. Integrated, automated workflows offer a path to consistent and efficient production.

  8. A Practical Guide To Autologous CAR T Manufacturing 6/19/2026

    Early process decisions shape scalability, consistency, and compliance in autologous CAR T manufacturing. Learn where variability emerges across the workflow and how to plan ahead.

  9. The Invaluable Asset Driving Advanced Therapies Forward 6/19/2026

    Cell therapies are advancing rapidly, but manufacturing delays still limit patient access. Improving operational understanding, reducing risk, and strengthening collaboration may be just as critical.

  10. Achieving High CAR T Cell Transduction Using An Automated Platform 6/19/2026

    Automation is reshaping CAR T manufacturing. A modular, closed approach with digital integration supports efficient workflows while maintaining critical functional performance under GMP conditions.